BioBridgeX
ServicesVendorsResources

IND-Enabling CRO & CDMO services

GLP toxicology and the regulatory package to file your IND. Source and compare qualified suppliers on BioBridgeX, and contract directly with the supplier you choose. Free for buyers.

Quick answer

IND-enabling services are the GLP-grade preclinical safety studies and regulatory authoring a sponsor completes before filing an FDA Investigational New Drug (IND) application. On BioBridgeX you source and compare qualified CRO and CDMO suppliers for GLP toxicology, safety pharmacology, genetic toxicology, DART, toxicokinetics, immunogenicity and immunotoxicology, and IND authoring, then contract directly with the suppliers you choose, all in one place. Free for buyers; suppliers pay a flat 2%.

IND-Enabling service categories

GLP Toxicology
Safety Pharmacology
Genetic Toxicology
Reproductive & Developmental Tox (DART)
Toxicokinetics (TK)
Immunogenicity & Immunotoxicology
IND / Regulatory Package Authoring
Regulatory Affairs & Consulting

What is the IND-enabling stage in drug development?

IND-enabling is the run-up to your first human dose. It is the body of nonclinical safety, pharmacology, and exposure work you finish so the FDA will let you open an Investigational New Drug (IND) application and start Phase 1. Everything in this stage answers one question a reviewer keeps front of mind: is it reasonably safe to put this molecule into a person, and at what dose do you begin.

The pivotal studies here run under Good Laboratory Practice (GLP), the quality system in 21 CFR Part 58, and they are designed against ICH and FDA guidance. The guideline that anchors most program plans is ICH M3(R2). One principle from it shapes the whole timeline: the duration of your repeat-dose toxicology has to support the duration of the human trial you want to run, so a longer or repeat-dose Phase 1 needs correspondingly longer tox, generally in two species.

After you submit, the IND goes into effect 30 calendar days after the FDA receives it, unless the agency notifies you sooner that you may proceed or places the program on clinical hold (21 CFR 312.40 and 312.42). The FDA reads the package for safety during that window. A clean IND-enabling package is what carries you through that review without a hold, and most of the work to build it gets outsourced to specialist CROs.

What CRO and CDMO services do buyers source at the IND-enabling stage?

Almost no biotech owns a GLP toxicology facility, so this stage is heavily outsourced. Sponsors either hand an end-to-end package to one full-service CRO or assemble specialists per workstream. On BioBridgeX you compare qualified suppliers across the categories that make up a filing-ready package and contract directly with the ones you choose, all in one place.

  • GLP Toxicology: the pivotal repeat-dose studies, typically in two species (one rodent, one non-rodent such as dog, minipig, or non-human primate), to set the No-Observed-Adverse-Effect-Level (NOAEL), find target organs, and define the exposure margins that justify your Phase 1 starting dose. This is the spine of the package and usually the critical path.
  • Safety Pharmacology: the core battery covering cardiovascular, central nervous system, and respiratory function, paired with an in vitro hERG assay for QT and cardiac arrhythmia risk and often an in vivo cardiovascular study in a telemetered species.
  • Genetic Toxicology: the genotox battery, commonly the Ames bacterial mutation test, an in vitro chromosomal aberration or micronucleus assay, and an in vivo micronucleus test, to screen for mutagenic and clastogenic liability before first-in-human.
  • Reproductive and Developmental Toxicology (DART): embryo-fetal development and fertility studies. Timing depends on your region and trial population, and it is one of the items to settle with the agency before you commit budget.
  • Toxicokinetics (TK): the exposure measurements built into the GLP tox studies that link the doses animals received to plasma concentrations, so the NOAEL is expressed in exposure terms a reviewer can map to humans. TK travels with the tox study and depends on validated bioanalytical methods.
  • Immunogenicity and Immunotoxicology: anti-drug antibody (ADA) assessment and immune-function endpoints, central for biologics, vaccines, and cell and gene therapies where the immune response itself can be the safety signal.
  • IND and Regulatory Package Authoring: the people who compile the nonclinical and CMC data into the Module 2 summaries and Module 4 nonclinical sections, write the Investigator's Brochure, and assemble the IND for submission. Many of these suppliers also help shape your pre-IND meeting strategy with the agency.

What is the difference between GLP, GMP, and GCP for IND-enabling work?

The quality standard you need depends on the workstream, and getting it wrong is one of the more expensive mistakes at this stage. GLP (Good Laboratory Practice, 21 CFR Part 58) governs the nonclinical safety studies: the pivotal toxicology, safety pharmacology, genotox, and DART that support human risk assessment. A reviewer checks GLP status early, and a study run non-GLP that a reviewer later expects in GLP has to be repeated, which is the multi-month, six-figure delay you were trying to avoid.

Not everything needs to be GLP, though, and treating it that way burns budget. Early dose-range-finding, a maximum-tolerated-dose read, a mini-Ames, early hERG, and preliminary ADME often run non-GLP so you can fail cheap and design the pivotal studies properly. Decide GLP status per study up front, and raise the close calls at your pre-IND meeting.

GMP (Good Manufacturing Practice) is a separate system that governs the drug substance and drug product you make for the clinic. The test article dosed in your GLP tox animals should match what goes into patients, so the manufacturing CDMO and the tox CRO have to stay coordinated. GCP (Good Clinical Practice) governs the Phase 1 trial that comes after the IND clears, so it sits just downstream of this stage. When you filter suppliers on BioBridgeX you can screen on GLP, GMP, and GCP attributes directly.

How do buyers choose an IND-enabling CRO?

Score two or three candidates against the same written scope rather than collecting quotes that measure different things. For IND-enabling work, regulatory intent usually outweighs everything else, so a GLP shop with a clean FDA inspection record beats a cheaper lab that has never supported a submission. The cheapest quote almost never wins here, because a repeated study or a clinical hold costs far more than the savings.

Match the supplier to your modality before anything else. Small molecules, monoclonal antibodies, ADCs, oligonucleotides, and cell and gene therapies each carry their own analytical and safety baggage, and a lab that is excellent at small-molecule tox may be a beginner at a non-human-primate biologic study or a vector biodistribution program. Ask how many comparable programs the team has finished and how many cleared a regulatory review.

  • Confirm GLP status (21 CFR Part 58) for every pivotal study and ask for the recent FDA inspection history before you sign.
  • Get the named study director in writing, not just a sales contact. The study director owns the GLP study and the report.
  • Pin down real capacity and a milestone timeline (protocol, in-life, analysis, draft report, final report), and ask what historically causes slippage. GLP slot availability is the binding constraint more often than the science.
  • Check that bioanalytical and TK methods are validated to the standard your submission needs, since exposure data underpins the whole safety story.
  • Confirm the supplier can run workstreams in parallel (genotox and safety pharmacology alongside the pivotal tox, not after it) so the timeline does not stack end to end.

How long do IND-enabling studies take and what drives the cost?

Plan on the better part of a year to roughly a year and a half for a clean small-molecule program from candidate selection to IND filing. Tightly sequenced teams compress that, and biologics usually run longer because of the added immunogenicity, biodistribution, and manufacturing work. Booking GLP tox slots well ahead is the single biggest lever on the calendar.

The critical path is almost always the longest repeat-dose tox study plus the lead time to manufacture and release test article, so reserving pivotal tox capacity early and running the other studies in parallel is just standard practice. The science rarely stalls a program; the schedule does.

On cost, think in relative magnitudes rather than a single headline figure. CMC for drug substance and drug product, together with the pivotal GLP toxicology, are typically the two largest line items. The non-rodent (for example, dog) tox study usually costs more than the rodent study, while genotox and the PK package are comparatively small. Biologics that require non-human-primate work cost more and schedule harder, and including women of childbearing potential in Phase 1 adds reproductive-tox expense. Get itemized quotes against one written scope; your real cost depends on the molecule, the modality, and the design of the first trial, so treat any published range as a rough planning anchor, not a fixed price.

Do biologics and cell or gene therapies need a different IND-enabling package?

The framework holds but the specifics shift hard by modality. Biologics still need GLP safety pharmacology and toxicology, but species selection is driven by pharmacological relevance rather than the default rodent-plus-non-rodent pair. For many monoclonal antibodies and oncology biologics the only pharmacologically relevant species is the non-human primate, which raises cost, ethical scrutiny, and scheduling complexity, and pushes immunogenicity and immunotoxicology to the front of the package.

The standard genotoxicity battery that makes sense for a small molecule usually is not run by rote for a large protein. Cell and gene therapies add their own layers: biodistribution, persistence, tumorigenicity, and vector-specific safety questions that a small-molecule tox lab is not set up to run. This is exactly why matching the supplier to your modality matters more than headline price.

Because BioBridgeX covers all indications and modalities, you can filter for suppliers that have actually run programs in your modality, whether that is a PROTAC degrader, an siRNA, an ADC, or a CAR-T, instead of forcing your program onto a generalist.

How does sourcing IND-enabling services through BioBridgeX work?

BioBridgeX is a neutral marketplace for outsourced drug development. It runs no lab work itself. It provides supplier qualification and structured quote comparison across your CRO and CDMO suppliers, so you can source GLP toxicology, safety pharmacology, genetic tox, DART, toxicokinetics, immunotox, and IND authoring in one place and contract directly with the suppliers you choose, instead of finding and chasing each lab on its own.

The practical win at this stage is the coordination tax it removes. A multi-supplier IND-enabling program normally means separate qualifications and audits, several master service agreements and work orders, scheduling dependencies between labs, and the program management to keep parallel studies on the critical path. BioBridgeX brings that into one place where you compare quotes and contract directly with every supplier you choose, while you keep the strongest provider for each workstream.

It is free for buyers, and suppliers pay a flat 2% success fee after you pay them, so there is no incentive to steer you toward a pricier lab. Supplier profiles are openly discoverable at biobridgex.com/vendors, so you can size up fit before any sales call, and coverage runs across the full lifecycle (discovery, preclinical, IND-enabling, clinical, and CMC/manufacturing), which means when your candidate clears IND-enabling you can move into GMP supply with the same coordinator. Buyers get matched at biobridgex.com/register; CRO and CDMO suppliers list their capabilities at biobridgex.com/cro/onboarding.

Frequently asked questions

What are IND-enabling studies?
IND-enabling studies are the preclinical safety, pharmacology, and exposure studies you complete before filing an Investigational New Drug (IND) application with the FDA. They show it is reasonably safe to dose humans for the first time and define a safe Phase 1 starting dose, a dose-escalation plan, and the safety parameters to monitor. The package centers on GLP toxicology, safety pharmacology, genetic toxicology, and toxicokinetics, plus DART and immunotoxicology depending on modality and trial population.
Which services make up an IND-enabling package?
A typical package covers GLP repeat-dose toxicology in two species, a safety pharmacology core battery (cardiovascular, CNS, respiratory) with an in vitro hERG assay, a genetic toxicology battery (Ames plus in vitro and in vivo assays), toxicokinetics built into the tox studies, reproductive and developmental toxicology (DART) where the trial population requires it, immunogenicity and immunotoxicology for biologics and advanced therapies, and IND regulatory authoring to compile and file the submission. Exact scope follows the molecule and the planned first trial under ICH M3(R2).
Why do IND-enabling toxicology studies have to be GLP?
Pivotal toxicology and safety pharmacology studies that support an IND must be run under Good Laboratory Practice (21 CFR Part 58) because that is the quality bar for data used in human risk assessment. Reviewers check GLP status closely. Early de-risking work such as dose-range finding, MTD reads, mini-Ames, and preliminary ADME can run non-GLP to save time and money, but a pivotal study run non-GLP that a reviewer later expects in GLP has to be repeated.
How long do IND-enabling studies take?
For a straightforward small molecule, plan on roughly a year to a year and a half from candidate selection to IND filing, and tightly sequenced programs run faster. Biologics generally take longer because of added immunogenicity, biodistribution, and manufacturing work. The critical path is usually the longest repeat-dose tox study plus the time to manufacture and release test article, so running genotox and safety pharmacology in parallel with the pivotal tox is how teams keep the timeline down.
How much do IND-enabling studies cost?
Cost varies widely by modality, study design, and where the work is run, so it is more useful to think in relative magnitudes than a single figure. CMC (drug substance and drug product) and the pivotal GLP toxicology are usually the two largest line items, the non-rodent tox study typically costs more than the rodent study, and genotox and the PK package are comparatively small. Biologics needing non-human-primate work cost more, and including women of childbearing potential in Phase 1 adds reproductive-tox expense. Get itemized quotes against one written scope rather than relying on a headline number.
How do I choose a CRO for IND-enabling studies?
Score two or three candidates against the same written scope, weight GLP compliance and FDA inspection history heaviest, and match the supplier to your modality. Confirm real capacity and a milestone timeline, get the named study director in writing, and check that bioanalytical and toxicokinetics methods are validated to the standard your submission needs. The cheapest quote rarely wins, because a repeated study or a clinical hold costs far more than the savings.
What is the difference between toxicokinetics and DMPK?
DMPK (drug metabolism and pharmacokinetics) characterizes how a compound is absorbed, distributed, metabolized, and excreted, usually in dedicated PK studies during preclinical development. Toxicokinetics is the exposure measurement built into the GLP toxicology studies themselves, linking the doses animals received to plasma concentrations so the NOAEL can be expressed in exposure terms a reviewer maps to humans. TK travels with the tox study; DMPK is a separate, earlier workstream.
When do I need reproductive and developmental toxicology (DART) before an IND?
It depends on your region and trial population. Under ICH M3(R2), preliminary embryo-fetal data can support limited enrollment of women of childbearing potential in early Phase 1 before the definitive DART studies are finished, while some regions take a more restrictive view and expect fertility and embryo-fetal data earlier. If your Phase 1 will include that population or run longer, settle DART timing with the agency at your pre-IND meeting before you commit budget.
Do biologics need immunogenicity and immunotoxicology testing for the IND?
Yes. For most biologics, vaccines, and cell and gene therapies the immune response is itself a safety question, so anti-drug antibody (ADA) assessment and immune-function endpoints are part of the IND-enabling work. Species selection for these programs is driven by pharmacological relevance, which often makes the non-human primate the only relevant species, and standard small-molecule genotoxicity batteries usually are not run for large proteins.
Can BioBridgeX coordinate an entire IND-enabling program across multiple suppliers?
Yes. BioBridgeX is a neutral marketplace that lets you source GLP toxicology, safety pharmacology, genetic tox, DART, toxicokinetics, immunotox, and IND authoring across multiple qualified CRO and CDMO suppliers in one place, comparing quotes and contracting directly with the supplier you choose. It coordinates supplier qualification and project management but performs no lab work itself, and the buyer pays the supplier directly. It is free for buyers, suppliers pay a flat 2% success fee after you pay them, and coverage extends into CMC/manufacturing so you can move into GMP supply through the same marketplace once the candidate clears.

Source IND-Enabling with one contract

Compare transparent quotes from qualified IND-Enabling CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes